A Texas researcher received a $219,000 NIH grant to study the potential of a treatment for radiation-induced pulmonary ...

Clinical trials are an important part of IPF research, says columnist Sam Kirton, but we need people willing to participate in them.

Over the coming months, the Pulmonary Fibrosis Foundation's 2025 PFF Walk will aim to raise more than $1 million for the ...

Living with pulmonary fibrosis, columnist Ann Reynoso writes, means no more independent, spontaneous days with enough energy ...

During the dog days of summer, columnist Sam Kirton takes special care to protect himself from medication side effects.

That’s according to top-line data from the Phase 2b CORAL trial (NCT05964335), which is evaluating three doses of the experimental oral therapy against a placebo, taken twice a day, in 165 adults.

A Phase 2 clinical trial has begun recruiting that’s assessing the safety and efficacy of LTI-03, Rein Therapeutics’ inhaled therapy for idiopathic pulmonary fibrosis (IPF). RENEW (NCT06968845) is ...

In people with IPF, however, senescence markers are more abundant than in healthy individuals, and the abnormal persistence of these cells has been linked to inflammation and scar tissue formation..

Sam Kirton started his column in November 2021 and writes from his home at Lake Anna, Virginia, where he lives with his wife Susan. His diagnosis at age 59 with idiopathic pulmonary fibrosis in ...

Although there is no cure for IPF, two antifibrotic medications have been approved to treat the condition: Esbriet (pirfenidone) and Ofev (nintedanib), both of which can slow lung function decline.